Skip to main content
Premium Trial:

Request an Annual Quote

William Parrett, Jason Novi, Robert Gavin, Wilhelm Lachnit, Tim Harkness

Thermo Fisher Scientific last week announced the election of William Parrett to its board.
Parrett has been appointed to the company’s audit committee.
Until his retirement last year, Parrett was at Deloitte Touche Tohmatsu for more than 40 years, most recently as global CEO.

Cell BioSciences this week announced Jason Novi has joined the company as its CFO. Also, Robert Gavin was named vice president, engineering, and Wilhelm Lachnit was named vice president, R&D.
Novi will be responsible for the finance, manufacturing, and administrative functions of the firm. Prior to Cell BioSciences, he was vice president of finance at Nektar Therapeutics. Between 2000 and 2007, he was director of finance at Molecular Devices.

Gavin was most recently director of engineering at MDS Analytical Technologies. Lachnit had most recently been at Molecular Devices where he held both scientific and commercial leadership positions.

Cell BioSciences is a startup nanofluidic systems firm. Last month it named Tim Harkness its president and CEO.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.